The Analisis Efektivitas Biaya Seftriakson Injeksi Dibandingkan dengan Siprofloksasin Injeksi pada Pasien Infeksi Saluran Kemih Rawat Inap di RSPAD Gatot Soebroto Tahun 2021-2022

Abstract

Urinary Tract Infection (UTI) is a condition that occurs when bacteria enters the urinary tract through the urethra and subsequently multiply within the bladder. In Indonesia, the prevalence of UTIs remains relatively high, with approximately 95 cases per 100.000 population per year. The aim of this study was to determine the cost-effectiveness of intravenous ceftriaxone therapy compared to intravenous ciprofloxacin therapy among inpatients with UTIs at the Indonesia Army Central Hospital Gatot Soebroto during the years 2021-2022. This retrospective research employed an observational design with a cross-sectional study approach, utilizing medical record data and cost perspectives from the hospital's standpoint. A total of 146 patients met the study criteria and were divided into two groups: the intervention group receiving intravenous ceftriaxone therapy and the comparator group receiving intravenous ciprofloxacin therapy. The data effectiveness based on length of hospital stay and total medical costs were analyzed using the Chi-Square test and the average cost-effectiveness ratio formula. The results indicated a significant difference in the effectiveness of the ceftriaxone group compared to the ciprofloxacin (p<0.05) and it was said to be effective if length of stay <11 days. Based on the ACER calculations, the cost-effectiveness of the intravenous ceftriaxone therapy group was Rp566,334/% effectiveness, while the intravenous ciprofloxacin therapy group was Rp987,182 /% effectiveness